Adam Feuerstein

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

 


Feuerstein graduated from Emory University with a bachelor's degree in political science.

 


Recent Articles By The Author

Mylan to Launch Cheaper Generic Alternative to EpiPen; Shares Rise

Mylan to Launch Cheaper Generic Alternative to EpiPen; Shares Rise

The drugmaker says it will launch the product in 'several weeks' at a list price of $300 per two-park carton.

Jabbing a Needle in the Overinflated Nymox Prostate Drug Hype

Jabbing a Needle in the Overinflated Nymox Prostate Drug Hype

Nymox will not be successful in convincing the U.S. Food and Drug Administration (or its counterpart in Europe) to approve fexapotide to treat men with enlarged prostates.

Amgen's Shameful Silence Covers Up Reasons for FDA Drug Rejection

Amgen's Shameful Silence Covers Up Reasons for FDA Drug Rejection

An Amgen drug to treat secondary hyperparathyroidism was rejected by U.S. regulators Wednesday but the biotech company offered no public explanation for why the drug's marketing application was denied.

Hillary Clinton Blasts Drug Prices, Biotech Stocks Plunge; Yes, It Could Be Happening Again

Hillary Clinton Blasts Drug Prices, Biotech Stocks Plunge; Yes, It Could Be Happening Again

The Nasdaq Biotechnology Index fell 3.5% heading into Wednesday's close, with the loss triggered by a statement from Clinton's presidential campaign blasting Mylan for 'outrageous' pricing of the EpiPen.

Cyclacel Stock Runs on Momentum Rocket Fueled by 'Dumb & Dumber' Optimism

Cyclacel Stock Runs on Momentum Rocket Fueled by 'Dumb & Dumber' Optimism

Shares of biotech micro-cap Cyclacel Pharmaceuticals have doubled in price in the past 10 days. Call it the Lloyd Christmas effect.